```
FILE 'HOME' ENTERED AT 08:29:04 ON 22 DEC 2008

=> b reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 08:29:14 ON 22 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 DEC 2008  HIGHEST RN 1087349-26-5
DICTIONARY FILE UPDATES:  19 DEC 2008  HIGHEST RN 1087349-26-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> S 151-21-3/RN
L1           1 151-21-3/RN

=> sel L1 chem
E1 THROUGH E236 ASSIGNED

=> b bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.82       1.03

FILE 'ADISCTI' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'ANABSTR' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (c) 2008 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)
```

FILE 'AQUALINE' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT 2008 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOENG' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 08:29:43 ON 22 DEC 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'BIOTECHNO' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 08:29:43 ON 22 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (c) 2008 DECHEMA eV

FILE 'CIN' ENTERED AT 08:29:43 ON 22 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'CROPU' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'DDFB' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'DISSABS' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'DRUGMONOG2' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'EMBAL' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'EMBASE' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'ESBIOBASE' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'FOMAD' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 International Food Information Service

FILE 'GENBANK' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'HEALSAFE' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 IMSWORLD Publications Ltd

FILE 'KOSMET' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'MEDLINE' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'NTIS' ENTERED AT 08:29:43 ON 22 DEC 2008
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2008)

FILE 'NUTRACEUT' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'OCEAN' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'PASCAL' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'PCTGEN' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'PHAR' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'PHARMAML' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'PHIN' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'PROMT' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'PROUSDDR' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'PS' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'RDISCLOSURE' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'SCISEARCH' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'SYNTHLINE' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'TOXCENTER' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'USGENE' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'USPATFULL' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'USPATOLD' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'USPAT2' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'VETB' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'VETU' ENTERED AT 08:29:43 ON 22 DEC 2008

FILE 'WATER' ENTERED AT 08:29:43 ON 22 DEC 2008

```
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'WPIFV' ENTERED AT 08:29:43 ON 22 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s e1-236 (s) (staphylococc? (5a) (protein (2a) a) or spa))
UNMATCHED RIGHT PARENTHESIS 'SPA))'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s e1-236 (s) (staphylococc? (5a) (protein (2a) a) or spa)
   1 FILES SEARCHED...
   2 FILES SEARCHED...
   3 FILES SEARCHED...
   4 FILES SEARCHED...
   5 FILES SEARCHED...
   6 FILES SEARCHED...
   7 FILES SEARCHED...
   8 FILES SEARCHED...
   9 FILES SEARCHED...
  10 FILES SEARCHED...
  11 FILES SEARCHED...
  12 FILES SEARCHED...
  13 FILES SEARCHED...
THE ESTIMATED SEARCH COST FOR FILE 'CAPLUS' IS 1,229.60 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:end

=> s (sds or (sodium (2a) docecyl) (s) (staphylococc? (5a) (protein (2a) a) or spa)
UNMATCHED LEFT PARENTHESIS '(SDS'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s (sds or (sodium (2a) docecyl)) (s) (staphylococc? (5a) (protein (2a) a) or spa)
  11 FILES SEARCHED...
  12 FILES SEARCHED...
  21 FILES SEARCHED...
  28 FILES SEARCHED...
  40 FILES SEARCHED...
  45 FILES SEARCHED...
  57 FILES SEARCHED...
  59 FILES SEARCHED...
  64 FILES SEARCHED...
L2        1028 (SDS OR (SODIUM (2A) DOCECYL)) (S) (STAPHYLOCOCC? (5A) (PROTEIN
               (2A) A) OR SPA)

=> s L2 (s) (skin or derm## or epiderm##)
  39 FILES SEARCHED...
L3          16 L2 (S) (SKIN OR DERM## OR EPIDERM##)

=> s L3 and py<2005
'2005' NOT A VALID FIELD CODE
   8 FILES SEARCHED...
  14 FILES SEARCHED...
  16 FILES SEARCHED...
'2005' NOT A VALID FIELD CODE
  27 FILES SEARCHED...
```

```
  29 FILES SEARCHED...
<------User Break------>

=> d rank
NO F-NUMBERS CURRENTLY EXIST


=> s L2 (s) (skin or derm## or epiderm##)
  59 FILES SEARCHED...
L4          16 L2 (S) (SKIN OR DERM## OR EPIDERM##)

=> d rank
NO F-NUMBERS CURRENTLY EXIST


=> d rank L4
'FULL' IS NOT VALID IN THE CURRENT FILE
This option is not valid in the current file.  Enter the command
without the option at the arrow prompt (=>).  Or, first enter the
file in which the saved item created.  Then enter the command and
option at an arrow prompt in the file.

=> d rank L4
'FULL' IS NOT VALID IN THE CURRENT FILE
This option is not valid in the current file.  Enter the command
without the option at the arrow prompt (=>).  Or, first enter the
file in which the saved item created.  Then enter the command and
option at an arrow prompt in the file.

=> L4 d rank
MISSING OPERATOR L4 D RANK
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d L4 ti

L4    ANSWER 1 OF 16  BIOENG  COPYRIGHT 2008 CSA on STN
TI    Contribution of IL-18 to atopic-dermatitis-like skin inflammation induced
      by Staphylococcus aureus product in mice


=> s L3 and py<2005
<------User Break------>

=> s L4 and py<2005
'2005' NOT A VALID FIELD CODE
   8 FILES SEARCHED...
  14 FILES SEARCHED...
  16 FILES SEARCHED...
'2005' NOT A VALID FIELD CODE
  28 FILES SEARCHED...
'2005' NOT A VALID FIELD CODE
  41 FILES SEARCHED...
  45 FILES SEARCHED...
'2005' NOT A VALID FIELD CODE
  50 FILES SEARCHED...
'2005' NOT A VALID FIELD CODE
  59 FILES SEARCHED...
L5           8 L4 AND PY<2005

=> d L5 ibib abs 1-8
```

L5 ANSWER 1 OF 8 BIOTECHNO COPYRIGHT 2008 Elsevier Science B.V. on STN
ACCESSION NUMBER: 2003:36963095 BIOTECHNO <<LOGINID::20081222>>
TITLE: The tryptic cleavage product of the mature form of the bovine desmoglein 1 ectodomain is one of the antigen moieties immunoprecipitated by all sera from symptomatic patients affected by a new variant of endemic pemphigus
AUTHOR: Abreu-Velez A.M.; Javier Patino P.; Montoya F.; Bollag W.B.
CORPORATE SOURCE: A.M. Abreu-Velez, Inst. for Molec. Med. and Genetics, Medical College of Georgia, CB 2803, 1120 15th Street, Augusta, GA 30912-2630, United States.
E-mail: aavelez@mail.mcg.edu
SOURCE: European Journal of Dermatology, (2003), 13/4 (359-366), 45 reference(s)
CODEN: EJDEE4 ISSN: 1167-1122
DOCUMENT TYPE: Journal; Article
COUNTRY: France
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2003:36963095 BIOTECHNO <<LOGINID::20081222>>
AB Multiple antigens are recognized by sera from patients with pemphigus foliaceus (PF). Several have been identified including keratin 59, desmocollins, envoplakin, periplakin, and desmogleins 1 and 3 (Dsg1 and Dsg3). In addition, an 80 kDa antigen was identified as the N-terminal fragment of Dsg1 using as antigen source an insoluble epidermal cell envelope preparation. However, still unsolved was the identity of the most important antigenic moiety, a 45 kDa tryptic fragment which is recognized by all sera from patients with fogo selvagem, pemphigus foliaceus, by half of pemphigus vulgaris sera and by a new variant of endemic pemphigus in El Bagre, Colombia that resembles Senear-Usher syndrome. Here, we report the identification of the 45 kDa conformational epitope of a soluble tryptic cleavage product from viable bovine epidermis. To elucidate the nature of this peptide, viable bovine epidermis was trypsin-digested, and glycosylated peptides were partially purified on a concanavalin A (Con-A) affinity column. This column fraction was then used as an antigen source for further immunoaffinity purification. A PF patient's serum covalently coupled to a Staphylococcus aureus protein A
column was incubated with the Con-A eluted products and the immuno-isolated antigen was separated by SDS-PAGE, transferred to a membrane, and visualized with Coomassie blue, silver and amido black stains. The 45 kD band was subjected to amino acid sequence analysis revealing the sequence, EXIK-FAAAXREGED, which matched the mature form of the extracellular domain of bovine Dsg1. This study confirms the biological importance of the ectodomain of Dsg1 as well as the relevance of conformational epitopes in various types of pemphigus.

L5 ANSWER 2 OF 8 BIOTECHNO COPYRIGHT 2008 Elsevier Science B.V. on STN
ACCESSION NUMBER: 1986:16044410 BIOTECHNO <<LOGINID::20081222>>
TITLE: High sensitive immunoadsorption procedure for detection of low-abundance proteins
AUTHOR: Platt E.J.; Karlsen K.; Lopez-Valdivieso A.; et al.
CORPORATE SOURCE: Department of Physiology-Anatomy, University of California, Berkeley, CA 94720, United States.
SOURCE: Analytical Biochemistry, (1986), 156/1 (126-135)
CODEN: ANBCA2
DOCUMENT TYPE: Journal; Article
COUNTRY: United States

LANGUAGE: English
AN 1986:16044410 BIOTECHNO <<LOGINID::20081222>>
AB A procedure that virtually eliminates nonspecific adsorption of radiolabeled proteins during immunoprecipitation was devised utilizing staphylococcal cells containing protein A (Staph A). Immunoprecipitates (antigen-antibody complexes) were solubilized from Staph A pellets into detergent micelles by incubation in a small volume of 1% sodium dodecyl sulfate (SDS) at 23°C for 10 min. To allow re-formation of immunocomplexes and rebinding to new Staph A, the SDS-solubilized material was diluted 20-fold in buffer containing 1% Triton X-100 and 0.5% sodium deoxycholate. Specific conductance measurements revealed that this solubilization and subsequent reimmunoadsorption of antibody-antigen complexes occur at SDS concentrations that are first above and then below its critical micelle concentration. This procedure lowered the nonspecific background from approximately 2250 parts per million (ppm) to less than 25 ppm with a final recovery of 30-50% depending on the antigen and antibody. Chaotropic agents such as 2 M urea, 0.2 M KOH, and 3.5 M MgCl.sub.2 (as well as combinations of urea and SDS) can substitute for 1% SDS, although the final recovery is somewhat lower. Fluorography of radiolabeled proteins obtained in this manner display virtually undetectable background even for exposure as long as 2 months. These methods allowed the unambiguous detection of low-abundance antigens at high level of sensitivity, for example, mouse mammary tumor virus protein products and epidermal growth factor receptor.

L5 ANSWER 3 OF 8 DRUGU COPYRIGHT 2008 THOMSON REUTERS on STN
ACCESSION NUMBER: 1985-19663 DRUGU P <<LOGINID::20081222>>
TITLE: Immunoprecipitation of HLA-DR Antigens from Gamma Interferon-Stimulated Cultured Human Keratinocytes.
AUTHOR: Wikner N; Kissinger M; Norris D; Clark Huff J; Weston W
LOCATION: Denver, Colorado, United States
SOURCE: J.Invest.Dermatol. (84, No. 4, 326, 1985)
CODEN: JIDEAE ISSN: 0022-202X
AVAIL. OF DOC.: Department of Dermatology, University of Colorado School of Medicine, Denver, CO., U.S.A.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature
AN 1985-19663 DRUGU P <<LOGINID::20081222>>
AB Effects of gamma interferon on the expression of HLA-DR antigenes were studied in cultured human keratinocytes. This study confirms by immunoprecipitation techniques that pure keratinocyte cultures can synthesize HLA-DR when stimulated by gamma interferon. (congress abstract).
ABEX Expression of HLA-DR antigens in the cells of the normal human epidermis is confirmed to the Langerhans cells and indeterminant cells. Keratinocytes, however, may stain for such Class II antigens in certain skin diseases characterized by monomuclear cell infiltrates, such as lichen planus, erythema multiforme, and graft vs. host disease. Second passage human keratinocytes isolated from neonatal foreskins were grown in serum-free, defined medium without a feeder layer. Keratinocyte cultures were stimulated for two days with recombinant human gamma interferon (0-50 units) and pulse labeled with 35S methionine. The cells were lysed and immunoprecipitation was performed with a monoclonal antibody to human HLA-DR (L243 IgC2a) and staphylococcal protein A. Evaluation of the immunoprecipitated proteins by SDS-polyacrylamide gel electrophoresis and autoradiography demonstrated labeled proteins with molecular weights corresponding to the alpha and beta chains of human

HLA-DR. The amount of HLA-DR synthesis was directly related to the dose of gamma interferon used for stimulation.

L5 ANSWER 4 OF 8 LIFESCI COPYRIGHT 2008 CSA on STN
ACCESSION NUMBER: 86:21291 LIFESCI <<LOGINID::20081222>>
TITLE: Highly sensitive immunoadsorption procedure for detection of low-abundance proteins.
AUTHOR: Platt, E.J.; Karlsen, K.; Lopez-Valdivieso, A.; Cook, P.W.; Firestone, G.L.
CORPORATE SOURCE: Dep. Physiol., Univ. California, Berkeley, CA 94720, USA
SOURCE: ANAL. BIOCHEM., (1986) vol. 156, no. 1, pp. 126-135.
DOCUMENT TYPE: Journal
FILE SEGMENT: F; L
LANGUAGE: English
SUMMARY LANGUAGE: English
AB A procedure that virtually eliminates nonspecific adsorption of radiolabeled proteins during immunoprecipitation was devised utilizing staphylococcal cells containing protein A (Staph A). Immunoprecipitates (antigen-antibody complexes) were solubilized from Staph A pellets into detergent micelles by incubation in a small volume of 1% sodium dodecyl sulfate (SDS) at 23 degree C for 10 min. To allow re-formation of immunocomplexes and rebinding to new Staph A, the SDS-solubilized material was diluted 20-fold in buffer containing 1% Triton X-100 and 0.5% sodium deoxycholate. Specific conductance measurements revealed that this solubilization and subsequent reimmunoadsorption of antibody-antigen complexes occur at SDS concentrations that are first above and then below its critical micelle concentration. The methods allowed the unambiguous detection of low-abundance antigens at a high level of sensitivity, for example, mouse mammary tumor virus protein products and epidermal growth factor receptor.

L5 ANSWER 5 OF 8 PASCAL COPYRIGHT 2008 INIST-CNRS. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 2003-0374741 PASCAL <<LOGINID::20081222>>
COPYRIGHT NOTICE: Copyright .COPYRGT. 2003 INIST-CNRS. All rights reserved.
TITLE (IN ENGLISH): The tryptic cleavage product of the mature form of the bovine desmoglein 1 ectodomain is one of the antigen moieties immunoprecipitated by all sera from symptomatic patients affected by a new variant of endemic pemphigus
AUTHOR: ABREU-YEEZ Ana Maria; JAVIER PATINO Pablo; MONTOYA Fernando; BOLLAG Wendy B.
CORPORATE SOURCE: Institute for Melecular Medicine and Genetics, Medical College of Georgia, CB 2803, 1120, 15th Street, Augusta, GA, 30912-2630, United States; Group of Primary immunodeficience, University of Autioquia, Medellin, Colombia, SA, Spain
SOURCE: EJD. European journal of dermatology, (2003) , 13(4), 359-366, 45 refs.
ISSN: 1167-1122
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: France
LANGUAGE: English
AVAILABILITY: INIST-22499, 354000112233370070
AN 2003-0374741 PASCAL <<LOGINID::20081222>>
CP Copyright .COPYRGT. 2003 INIST-CNRS. All rights reserved.
AB Multiple antigens are recognized by sera from patients with pemphigus

foliaceus (PF). Several have been identified including keratin 59, desmocollins, envoplakin, periplakin, and desmogleins 1 and 3 (Dsgl and Dsg3). In addition, an 80 kDa antigen was identified as the N-terminal fragment of Dsgl using as antigen source an insoluble epidermal cell envelope preparation. However, still unsolved was the identity of the most important antigenic moiety, a 45 kDa tryptic fragment which is recognized by all sera from patients with fogo selvagem, pemphigus foliaceus, by half of pemphigus vulgaris sera and by a new variant of endemic pemphigus in E1 Bagre, Colombia that resembles Senear-Usher syndrome. Here, we report the identification of the 45 kDa conformational epitope of a soluble tryptic cleavage product from viable bovine epidermis. To elucidate the nature of this peptide, viable bovine epidermis was trypsin-digested, and glycosylated peptides were partially purified on a concanavalin A (Con-A) affinity column. This column fraction was then used as an antigen source for further immunoaffinity purification. A PF patient's serum covalently coupled to a Staphylococcus aureus protein A
column was incubated with the Con-A eluted products and the immuno-isolated antigen was separated by SDS-PAGE, transferred to a membrane, and visualized with Coomassie blue, silver and amido black stains. The 45 kD band was subjected to amino acid sequence analysis revealing the sequence, EXIK-FAAAXREGED, which matched the mature form of the extracellular domain of bovine Dsgl. This study confirms the biological importance of the ectodomain of Dsgl as well as the relevance of conformational epitopes in various types of pemphigus.

L5 ANSWER 6 OF 8 PHIN COPYRIGHT 2008 Informa UK Ltd on STN

ACCESSION NUMBER: 86:12718 PHIN <<LOGINID::20081222>>
DATA ENTRY DATE: 17 Dec 1986
TITLE: Company news round-up: 1986
SOURCE: Animal-Pharm (1986) Review issue, January 5 1987 p13
DOCUMENT TYPE: Newsletter
FILE SEGMENT: FULL

L5 ANSWER 7 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2003:165856 USPATFULL <<LOGINID::20081222>>
TITLE: Protein kinase peptide substrate determination using peptide libraries
INVENTOR(S): Blackburn, Robert Kevin, Durham, NC, UNITED STATES
Bramson, Harold Neal, Durham, NC, UNITED STATES
Moyer, Mary Benbow, Durham, NC, UNITED STATES
Stuart, James Darren, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20030113711	A1	20030619	<--
APPLICATION INFO.:	US 2002-155481	A1	20020524 (10)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-294365P	20010530 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 1951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of isolating and identifying peptide substrates for a protein kinase is disclosed. The method involves a combination of size exclusion and gallium-based metal affinity chromatography. The method includes the steps of incubating a protein kinase with a peptide library in the presence of kinase reaction components, the library comprising library members; separating library members from the kinase reaction components using size exclusion chromatography to give a pool of phosphopeptides and unphosphorylated peptides; contacting the pool with immobilized gallium ions to form chelated phosphopeptides; eluting chelated phosphopeptides away from the gallium ions to give eluted phosphopeptides; sequencing the eluted phosphopeptides, whereby a preferred amino acid sequence of a preferred peptide substrate for a protein kinase is elucidated. Also disclosed is a method of identifying a compound that modulates the protein kinase catalyzed phosphorylation of a peptide substrate and a method of designing protein kinase substrates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 8 WPIDS COPYRIGHT 2008 THOMSON REUTERS on STN
DOC. NO. CPI: C2005-003766 [01]
DOC. NO. NON-CPI: N2005-010801 [01]
TITLE: Screening inhibitor of IL-18 production in subject suffering from atopic dermatitis by administering agent into keratinocytes of subject to stimulate IL-18, and administering substance into keratinocytes to inhibit IL-18
DERWENT CLASS: B04; D16; P14; S03
INVENTOR: MIZUTANI H; NAKANISHI K; TSUTSUI H
PATENT ASSIGNEE: (NISC-N) JAPAN SCI & TECH AGENCY; (NISC-N) JAPAN SCI & TECHNOLOGY AGENCY; (MIZU-I) MIZUTANI H; (NAKA-I) NAKANISHI K; (TSUT-I) TSUTSUI H
COUNTRY COUNT: 107

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC	
WO 2004104578	A1	20041202	(200501)*	JA	49[9]		<--
EP 1635176	A1	20060315	(200620)	EN			
JP 2005506315	X	20060720	(200648)	JA	26		<--
AU 2004241513	A1	20041202	(200654)	EN			<--
KR 2006011837	A	20060203	(200660)	KO			
CN 1777807	A	20060524	(200663)	ZH			
US 20070092448	A1	20070426	(200730)	EN			
AU 2004241513	B2	20070920	(200801)	EN			
AU 2007242943	A1	20080110	(200827)#	EN			

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004104578	A1	WO 2004-JP5747	20040421
AU 2004241513	A1	AU 2004-241513	20040421
AU 2004241513	B2	AU 2004-241513	20040421
CN 1777807	A	CN 2004-80010993	20040421
EP 1635176	A1	EP 2004-728686	20040421
EP 1635176	A1	WO 2004-JP5747	20040421

JP 2005506315 X	WO 2004-JP5747 20040421
KR 2006011837 A	WO 2004-JP5747 20040421
US 20070092448 A1	WO 2004-JP5747 20040421
JP 2005506315 X	JP 2005-506315 20040421
KR 2006011837 A	KR 2005-720134 20051022
US 20070092448 A1	US 2006-554301 20061206
AU 2007242943 A1 Div Ex	AU 2004-241513 20040421
AU 2007242943 A1	AU 2007-242943 20071212

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 1635176	A1	Based on	WO 2004104578	A
JP 2005506315	X	Based on	WO 2004104578	A
AU 2004241513	A1	Based on	WO 2004104578	A
KR 2006011837	A	Based on	WO 2004104578	A
AU 2004241513	B2	Based on	WO 2004104578	A

PRIORITY APPLN. INFO: JP 2003-120630 20030424
AU 2007-242943 20071212

AN 2005-013390 [01] WPIDS

AB WO 2004104578 A1 UPAB: 20050707

NOVELTY - Screening (M1) inhibitor of interleukin (IL)-18 production in a subject suffering from atopic dermatitis (AD), comprising inducing the production of IL-18 by administering a stimulating agent into keratinocytes of subject under in vivo or in vitro conditions, and administering a candidate substance into keratinocytes that inhibits the production of IL-18, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a serological therapeutic drug (I) comprising inhibitor obtainable by (M1);

(2) inducing (M2) AD, comprising administering Staphylococcus aureus origin protein A (SpA) or transplanting a skin having AD-like inflammatory lesion, to an organism;

(3) an animal model obtainable by (M2); and

(4) a screening kit for carrying out (M1) or (M2).

ACTIVITY - Antiinflammatory; Dermatological.

MECHANISM OF ACTION - Inhibitor of IL-18 (claimed).

No supporting data is given.

USE - (M1) is useful for screening inhibitor of IL-18 production in a subject suffering from AD (claimed). (I) is useful for treating atopic dermatitis.

DESCRIPTION OF DRAWINGS - The drawing is a graph representing the levels of IgE induced by the transplantation of skin having atopic dermatitis-like inflammatory lesion to a host.

=> logoff